Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

There are two ways of looking at this from ENTA’s perspective. The bearish take is that COVID antivirals aren’t needed in adults under age 65 lacking major risk factors, limiting the addressable market for EDP-235. The bullish viewpoint is that Paxlovid isn’t potent enough to help low-risk patients, but a superior drug such as EDP-235 could find an opening where Paxlovid has been shown to be ineffective.

The market seems to agree with the bearish take, as least for today.

I scanned the paper and chances for hospitalization for those under 65 and not immunized was greatly reduced by Paxloid treatment. That means the market is broader than just the over 65. By the way, the over 65 with risk factors is still a pretty high market.